Skip to main content

A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.

Item Preview

SIMILAR ITEMS (based on metadata)